Telehealth pushes multi-cancer blood tests before evidence of benefit

Also: The dispute between Corcept Therapeutics and the FDA runs deep ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­  

February 6, 2026 Check out STAT+

Sponsored By

Good morning. Angus Chen, STAT's cancer reporter, here. Last year, I wrote about the 57% cut to the Congressionally Directed Medical Research Program, which gutted funding marked for specific cancers. Areas like lung cancer and pancreatic cancer were left with zero dollars set aside. This week, though, Congress restored some of this critical research program, putting $1.27 billion dollars toward the CDMRP. This remains a cut from the roughly $1.5 billion dollars that CDMRP had typically received, but health advocates still see the move as a victory. "I'm incredibly proud of how our community and the broader cancer community came together, raised our voices, and secured historic funding for cancer research," wrote Julie Fleshman, president and CEO of PanCAN, in a blog post. The NIH budget also increased to $47.2 billion, a $415 million increase. The NCI's budget came to $7.35 billion, a $128 million increase.

Adobe STAT+ | Hims, other telehealth platforms push multi-cancer detection tests before evidence of benefit Multi-cancer blood tests promise early detection, but experts warn of misleading patients with false negatives or unneeded care with false positives. By Katie Palmer STAT+ | Dispute between Corcept Therapeutics, FDA runs deep Concerns over a potential risk of liver injury induced by the company's treatment, relacorilant, raise doubts. By Adam Feuerstein What to know about TrumpRx, the Trump administration's prescription drug platform Will TrumpRx accept insurance? Is TrumpRx open to all? Answers to frequently asked questions as White House unveils new portal that partners with GoodRx By Elaine Chen, John Wilkerson, and Chelsea Cirruzzo Camille MacMillin/STAT The FDA wants to rein in drug ads. On Super Bowl Sunday, it will be business as usual Little appears to have changed in the eyes of the industry since the Food and Drug Administration said it would crack down on pharma ads. By Damian Garde

More around STAT

---

In case you missed it More than one-third of cancer cases are preventable, massive study finds, Nature Israel accused of spraying cancer-linked herbicide on farms in southern Lebanon, the Guardian Living near hazardous waste sites may raise risk of more aggressive breast cancer, research finds, WLRN

---

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2026, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser